



We are pleased to announce today that BioMedica Diagnostics (BMD) has purchased the specialty coagulation business and product line from Sekisui Diagnostics (SDG).

The agreement includes all aspects of the business worldwide, with the exception of Europe, Middle East and Africa, where SDGmbH, a Sekisui Diagnostics subsidiary, will continue to distribute and support the products in partnership with BMD. In conjunction with this agreement, BMD will also acquire the American Diagnostica trademark. Both BMD and SDG are committed to a seamless transition where maintaining exceptional product quality and the highest service levels for all customers and partners are our top priorities.

The agreement closed as of December 1st, 2016 and from this time forward BMD will be responsible for the operation of the business.

Established in 1999, we are a diagnostics company with a focus on providing customized diagnostic solutions in human and animal health. The acquisition of these assets is a natural fit to further solidify our foundation in thrombosis and haemostasis and expand our reach in specialty coagulation.

We look forward to continuing to serve customers with the outstanding level of quality and service that partners have come to expect from BMD and SDG.

For more information about BioMedica Diagnostics or to purchase products, please contact Nadine Williams at +1-902-798-0982 or nwilliams@biomedicadiagnostics.com.